xtant medical holdings inc (BONE) Key Developments
Xtant Medical Holdings, Inc. Presents at Singular Research 10th Annual "Best of the Uncovereds" Conference, Sep-17-2015
Aug 26 15
Xtant Medical Holdings, Inc. Presents at Singular Research 10th Annual "Best of the Uncovereds" Conference, Sep-17-2015 . Venue: Luxe Sunset Bel Air Hotel, 11461 Sunset Boulevard, Los Angeles, CA 90049, United States.
Xtant Medical Holdings, Inc.'s Subsidiary Bacterin International, Inc. Announces FDA Approval of OsteoSelect(R) PLUS
Aug 25 15
Xtant Medical Holdings, Inc. announced that its wholly owned subsidiary, Bacterin International, Inc., has received FDA 510(k) clearance of OsteoSelect PLUS Demineralized Bone Matrix (DBM) Putty. OsteoSelect PLUS is a next-generation DBM putty, comprised of OsteoSelect Putty with the addition of demineralized cortical chips. Aligned with the Company's commitment to patient safety, OsteoSelect PLUS will provide another Sterile grafting solution for customers. This new product will also eliminate the need to mix bone chips and DBM putty intra-operatively, saving time and reducing graft variability. With this notice and clearance from the FDA, Xtant Medical is prepared to launch OsteoSelect PLUS to customers in Fourth Quarter 2015. The company will work with its primary GPO and IDN customers to add this product to current contracts, making it available immediately upon product launch. This is the first 510(k) approval for Bacterin International since becoming a subsidiary of Xtant Medical, and will be the first of many planned product releases, as management focuses on rounding out the combined product portfolio. This new product will help drive the Company's growth and provides an opportunity for increased market share.
Xtant Medical Holdings, Inc. Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-09-2015 12:05 PM
Aug 13 15
Xtant Medical Holdings, Inc. Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-09-2015 12:05 PM. Venue: The St. Regis Hotel, Two East 55th Street, New York, NY 10022, United States. Speakers: Daniel S. Goldberger, Chief Executive Officer, David Louis Kirschman, Chief Scientific Officer, Executive Vice President and Director, John P. Gandolfo, Chief Financial Officer, Treasurer and Secretary.
Xtant Medical Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for Second Half and Full Year 2015 and Full Year 2016
Aug 12 15
Xtant Medical Holdings, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $9,892,615 against $8,883,932 a year ago. Loss from operations was $1,383,291 against $1,332,009 a year ago. Net loss from operations before income taxes was $2,895,977 against $1,900,430 a year ago. Net loss was $2,895,977 or $0.41 per basic and diluted share against $1,900,430 or $0.35 per basic and diluted share a year ago. LBITDA was $918,182 million compared $769,645 a year ago. The higher revenues reflect increased penetration of targeted markets and an increase in internal and external sales resources compared to prior periods. The increased loss primarily reflects increased sales and marketing expenses associated with the company's ongoing execution of its strategy to increase and enhance field sales assets to drive future revenue growth.
For the six months, the company reported total revenue of $19,395,729 against $17,796,902 a year ago. Loss from operations was $3,115,960 against $2,524,010 a year ago. Net loss from operations before income taxes was $7,072,781 against $6,040,685 a year ago. Net loss was $7,072,781 or $1.02 per basic and diluted share against $6,040,685 or $1.11 per basic and diluted share a year ago. Net cash used in operating activities was $4,090,237 against $3,870,558 a year ago. Purchases of property and equipment and intangible assets were $70,441 against $115,202 a year ago. LBITDA was $2,224,766 compared to $1,484,829 in the prior year. Pro forma Loss from operations was $3,379,962 compared to $1,568,487 in the prior year. Pro Forma EBITDA was $1,192,215 compared to $2,463,555 in the prior year.
For the second half of 2015, the company has updated its guidance to reflect its recent acquisition of X-spine. The company is providing second half 2015 revenue guidance for the combined company in the range of $43 million to $46 million and second half 2015 EBITDA guidance within the range of $2.0 million and $2.5 million, excluding one time, non-recurring transaction expenses.
For the full year 2015, the company's gross margins are expected to 64% to 66%. EBITDA to be between $3.2 million and $3.7 million
For full year 2016, the company is projecting revenues in the range of $100 million to $105 million and EBITDA of approximately $7.0 to $9.0 million. Gross margins are expected to 65% to 67%. EBITDA to be between $7 million and $9 million.
Bacterin International Holdings, Inc. to Report Q2, 2015 Results on Aug 12, 2015
Aug 4 15
Bacterin International Holdings, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 12, 2015